< Update

AsperGenius®

Detection and identification of Aspergillus fumigatus, Aspergillus terreus, Aspergillus species and azole-resistance markers

50 reactions

Products & Targets

Products

PN-001 AsperGenius® Species multiplex kit (50 rxn)  

Species multiplex

  • Aspergillus fumigatus    
  • Aspergillus terreus
  • Aspergillus species
  • Internal Control (IC)
PN-002   AsperGenius® Resistance multiplex kit (50 rxn)

Species multiplex

  • Aspergillus fumigatus    
  • Aspergillus terreus
  • Aspergillus species
  • Internal Control (IC)

Resistance multiplex

  • L98H
  • Tandem repeat 34
  • T289A
  • Y121F

Features and benefits

  • Direct detection in BAL samples
  • Sample to result within 3.5 hours
  • Differentiation of A. fumigatus, A. terreus and A. species
  • Identification of azole-resistant markers: L98H/TR34 and TR46/Y121F/T289A
  • Internal Control (IC) and Positive Controls (PCs) included       
  • Dedicated DNA extraction protocol
  • Allows for timely, targeted antifungal treatment resulting in improved clinical outcome
  • Extensively clinically validated (published)


Real-time PCR instruments

  • LightCycler 480 II (Roche)
  • Rotor-Gene Q (Qiagen)
  • CFX96 (Biorad)
  • Mic qPCR (Bio Molecular Systems)
  • Quantstudio 5 (Thermo Fisher Scientific)


Diagnostic specimens

  • Bronchoalveolar lavage (BAL) samples
  • Serum samples
  • Plasma samples
  • Biopsy, CSF samples (not validated)


DNA extraction

  • NucliSENS EasyMAG (bioMérieux)


Quality

  • Validated on fungal cultures
  • Validated on clinical samples (BAL)
  • Validated on serum-, plasma samples
  • Validated on EQA programmes of QCMD

Background

Invasive pulmonary aspergillosis (IPA) is the most frequent invasive mold infection in immunocompromised patients and is mainly caused by Aspergillus fumigatus (A. fumigatus).
Aspergillus species are responsible for over 200,000 cases of IPA annually, and global estimates suggest that over 1.2 million patients have chronic pulmonary aspergillosis (CPA) and 4.8 million suffer from allergic bronchopulmonary aspergillosis (ABPA). The survival rates of immunocompromised patients with invasive aspergillosis have improved dramatically due to many factors, one of which is the availability of azole antifungal drugs. A number of these azoles have activity against aspergillus infections, including itraconazole, voriconazole, posaconazole and most recently isavuconazole. Voriconazole is normally the recommended first line therapy for IPA. However, azole resistance in A. fumigatus has been reported increasingly over the past decade with prevalence rates varying between 1.0% and 20.0%

References

Chong et al., BAL validation, JCM 2015 Mar;53(3):868-74

White et al., Serum validation, JCM, 2015 Jul;53(7):2115-21

Chong et al., Multicenter study, JAC 2016 Dec;71(12):3528-3535

Chong et al., Sibling species, Diagn Microbiol Infect Dis. 2017 Mar;87(3):247-252

White et al., Plasma validation, JCM, 2017 Aug;55(8):2356-2366

Montesinos et al., Methods azole-resistance, JCM, 2017 Aug;55(8):2391-2399

Schauwvlieghe et al., Co-infection wt-mut, JAC, 2017 Nov 1;72(11):3047-3050

Guegan et al., Cystic fybrosis, Front Microbiol. 2018 Mar 27;9:531

Tsitsopoulou et al., Environmental resistance, Front Microbiol. 2018 Jun 26;9:1395

Abdolrasouli et al., Resistance, JAC, 2018 Nov 52(5):637-642

Pelzer et al., Allogeneic HSCT, Med Mycol, 2019, May 21

PathoNostics Extraction kit

Cras mattis consectetur purus sit amet fermentum

DNA extraction

  • PN-502 PathoNostics Extraction kit
  • 50 reactions
  • Solution A (lysis buffer)
  • Solution B (neutralization buffer)

Quality

  • Validated on fungal cultures
  • Validated on nail, hair, skin samples
  • Validated on EQA programmes of QCMD
  • CE-IVD marked

Please contact us if you need more information.

Contact us